Key statistics
On Friday, Aurinia Pharmaceuticals Inc (AUPH:NMQ) closed at 8.63, -19.12% below its 52-week high of 10.67, set on Dec 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.06 |
---|---|
High | 9.13 |
Low | 8.61 |
Bid | 8.63 |
Offer | 8.95 |
Previous close | 9.07 |
Average volume | 2.17m |
---|---|
Shares outstanding | 135.10m |
Free float | 132.86m |
P/E (TTM) | 32.85 |
Market cap | 1.23bn USD |
EPS (TTM) | 0.2761 USD |
Data delayed at least 15 minutes, as of Jul 18 2025 21:00 BST.
More ▼
- Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
- Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
- New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
- Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
- Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
- Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
- ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
- Concerned Shareholders of Aurinia Pharmaceuticals Announce Their Intention to Withhold Support for CEO Peter Greenleaf at 2025 Annual Meeting
More ▼